One of the most important things we have been in need of is a way to test for cancers super early, years before there is a tumor. Current medical science cannot detect anything smaller than a pea and even bigger ones often get missed.
Screening methods currently being used are delivering unnecessary cumulative amounts of radiation. CT scans deliver as much as 500 times the radiation of a standard X-ray. PET scans are even worse, because the whole body is exposed to radiation.
Mammograms use ionizing radiation at a relatively high dose, which can contribute to the mutations that can lead to breast cancer. You can get as much radiation from one mammogram as you would from 1,000 chest X-rays. Mammography also compresses your breasts tightly, which can lead to a dangerous spread of cancerous cells, should they exist. Dr. Samuel Epstein, one of the world’s top cancer experts, has stated: “The premenopausal breast is highly sensitive to radiation, each 1 radiation exposure increases breast cancer risk by about 1 percent, with a cumulative 10 percent increased risk for each breast over a decade’s screening.”
Now there is a revolutionary new blood test that can detect cancer at its earliest stages!
The ONCOblot® blood test can detect tumors as small as 2 mm in diameter, which represents about 2 million cells (as early as Stage 0). It can find tumors years before conventional scans. This makes it much more sensitive than a typical scan. If cancers can be detected at this early stage, and distinguished as to tissue of origin, then this alone represents a huge advance in the cancer field. To give this a little perspective, mammograms pick up breast cancers when 1 billion cancer cells are present to form the lump, or when the tumor is around 10-20 mm in size. This. Is. Huge!
ONCOblot® identifies a specific type of protein in the blood, ENOX2, which exists only on the surface of a malignant cancer cell. The ENOX2 proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for early detection in both primary and recurrent cancer. It’s organ specific, meaning it can often tell where the cancer is located.
According to the ONCOblot® website, their database contains over 800 specimen containing examples of ENOX2 protein expression for the following cancers:
Bladder, Breast, Cervical, Colorectal, Endometrial, Esophageal, Follicular, Gastric, Hepatocellular, Kidney, Leukemia, Non-Small Cell, Lung Small Cell, Lymphoma, Melanoma, Mesothelioma, Myeloma, Ovarian, Pancreatic, Papillary, Prostate, Sarcoma, Squamous Cell, Uterine, and Testicular Germ Cell.
If there is more than one tissue of origin, then more than one type of ENOX2 would be revealed and the results would indicate each tissue of origin.
MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot® Test recently completed a published, peer reviewed retrospective clinical study focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot® test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.
This test has to be ordered by a physician. The price varies according to a number of factors, but I have not seen it for less than $850 since I have been looking into it – well worth the money, in my opinion. It is not covered by insurance at this time, as it is a relatively new test. It takes approximately 15 full business days (three weeks) to get results. If your physician’s office does not perform blood draws in their office, there are a few labs, such as Any Lab Test Now® who will perform the draw (check their website for the location closest to you). Check the ONCOblot® website for more options if neither of those works for you!
References:
oncoblotlabs.com
ralphmossblog.com
eurekalert.org
